New combo therapy aims to shrink kidney tumors before surgery
NCT ID NCT07172386
First seen Oct 31, 2025 · Last updated Jun 11, 2026 · Updated 34 times
Summary
This study tests a three-part treatment for people with advanced kidney cancer. First, doctors block the tumor's blood supply. Then, patients receive two drugs (toripalimab and axitinib) for several months before surgery. After surgery, they continue one drug for a year. The goal is to see if this approach makes surgery more successful and safe. About 40 adults with certain stages of kidney cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.